Neuro-Ophthalmology News

The FDA has issued a complete response letter to AstraZeneca for its supplemental biologics license application of Ultomiris to treat adults with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive.

Treatment with inebilizumab was effective in reducing two telltale signs of an attack of neuromyelitis optica spectrum disorder, Bruce A. Cree, MD, PhD, MAS, said in this Healio video.

BOSTON — Results from the long-term RESTORE study show patients with Leber hereditary optic neuropathy with ND4 mutation who were treated with Lumevoq had sustained improvement of best-corrected visual acuity in both eyes.

Horizon Therapeutics recently announced new MRI imaging data from a phase 3 clinical trial, which demonstrated that Uplizna reduced formation of asymptomatic optic nerve lesions in patients with neuromyelitis optica spectrum disorder.

Quantitative pupillometry may be a reliable method of assessing clinically intoxicated patients in EDs, per a study published in the Journal of the American College of Emergency Physicians Open.

An OCT study on spaceflight crew members found ocular morphology alterations potentially related to weightlessness and chronic headward fluid shift were not reversed by short-duration lower body negative pressure countermeasures.

Self-reported symptoms of anxiety and depression were higher among men aged 50 years and older with vision impairment, compared with those with normal vision, study findings showed in International Health.

SEATTLE – Inebilizumab was shown to be safe and effective in preventing relapses in individuals with neuromyelitis optica spectrum disorder, a speaker said at the 2022 American Academy of Neurology annual meeting.

A significant improvement of visual acuity was reported in eyes treated with a unilateral intravitreal injection of lenadogene nolparvovec for Leber hereditary optic neuropathy, researchers reported at the 2022 American Academy of Neurology annual meeting.

Natalia S. Rost, MD, MPH, chair of the AAN science committee, led a discussion to highlight select studies being presented at the AAN’s annual meeting April 2-7 in Seattle.